Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Cannabinoids (Indazole carboxamides)

ADB-FUBINACA

C21H23FN4O2 CAS 1185282-00-1 Analytical reference material — not for human consumption
ADB-FUBINACA, educational illustration of the molecular structure
Educational illustration of the molecular structure. This is not a photograph of the product.
Preferred name
ADB-FUBINACA
IUPAC name
N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide
Parent CAS number (reference)
1185282-00-1
Molecular formula
C21H23FN4O2
Molecular weight
382.4 g/mol
InChIKey
ZSSGCSINPVBLQD-GOSISDBHSA-N
PubChem
CID 58124399
Source
PubChem
Verified synonyms & catalog abbreviations
ADBFUBINACA ADB FUBINACA

Verified Neurochemical & Toxicological Intelligence

ADB-FUBINACA (ADMB-FUBINACA)

Synthetic Cannabinoid Receptor Agonist (High-Potency Full CB1/CB2 Agonist) Indazole-3-carboxamide (1-(4-fluorobenzyl) tert-leucinamide synthetic cannabinoid)
Verified PubChem & CAS Identity C21H23FN4O2 · CAS 1445583-51-6 · CID 70969086
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 382.44 g/mol
Peer-Reviewed & Agency Citations 4 · verified sources

Receptor Telemetry & Mechanism of Action

CB₁ Central Cannabinoid Receptor Full Agonist (Sub-nM)
CB₂ Peripheral Cannabinoid Receptor Full Agonist

Originally patented by Pfizer in 2009 (WO 2009/106980-A2; patent CAS 1185282-00-1), ADB-FUBINACA acts as a sub-nanomolar **full agonist** at human CB1 (**Ki = 0.36 nM; EC50 = 0.98–1.2 nM**, Emax ~3x JWH-018 and **up to 140-fold more potent than Delta9-THC**) and CB2 receptors (**EC50 = 3.5 nM**). In vitro neurotoxicology studies (2025, PMID 40480473) show PGC-1alpha dysregulation and mitochondrial fragmentation in differentiating neurons, while clinical/autopsy cases link exposure to seizures, rhabdomyolysis, kidney damage, and fatal coronary arterial thrombosis.

Biotransformation & Active Metabolites

Human hepatocyte incubations identify 23 metabolites dominated by hydroxydimethylpropyl-, hydroxydehydrodimethylpropyl-, and hydroxylindazole-ADB-FUBINACA urinary biomarkers.

Temporal Pharmacokinetics

Almost immediate (10–15 second onset), compact (up to 60 minute) full-CB1 rush producing heavy physical immobilization and mood elevation at low microgram levels, escalating abruptly into paranoia, chest pain, convulsions, and coma if exceeded.

  1. Onset 10–15 seconds inhaled
  2. Peak Window 10–25 minutes inhaled
  3. Total Window up to 60 minutes inhaled (longer orally or in toxic exposures)
  4. Residual / Half-Life 1–4 hours of residual somnolence and memory impairment; rapidly and extensively metabolized hepatically, though formal human plasma half-life is unverified.

UP TO 140x THC POTENCY + FULL-AGONIST CARDIOTOXICITY: Although isolated drug-forum posts cited by Swedish public health authorities mentioned 0.5–1 mg (500–1,000 ug), forensic toxicology links sub-milligram/milligram exposures directly to coma, seizures, rhabdomyolysis, kidney damage, and fatal coronary thrombosis. Volumetric microgram measurement is strictly required.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
25–50 ug (0.025–0.05 mg — tentative microgram estimate)
Cognitive & Sensory

Rapid onset of mild relaxation, sensory softening, and time slowing within 10–15 seconds.

Somatic & Autonomic

Faint bodily warmth and mild pulse elevation.

Light
50–125 ug (0.05–0.125 mg — tentative microgram estimate)
Cognitive & Sensory

Warm cannabimimetic mood elevation, music immersion, and calm mental deceleration.

Somatic & Autonomic

Dry mouth, red eyes, soft limb heaviness, and appetite increase.

Common Reference
125–250 ug (0.125–0.25 mg — tentative microgram estimate)
Cognitive & Sensory

Intense 'stoned' sedation, strong time distortion, short-term memory loss, and altered perception.

Somatic & Autonomic

Marked motor suppression, tachycardia, dizziness, and strong urge to lie down.

Strong
250–500 ug (0.25–0.50 mg — tentative microgram estimate)
Cognitive & Sensory

Severe confusion, hallucinations, agitation, acute paranoid anxiety, and loss of memory.

Somatic & Autonomic

Chest pain, hypertension, severe tachycardia, vomiting, fever, and abrupt somnolence.

Heavy / Toxic Zone
500+ ug (0.50+ mg — forum-reported 0.5–1 mg range overlaps severe/fatal clinical poisonings)
Cognitive & Sensory

Loss of consciousness / coma or severe agitated delirium.

Somatic & Autonomic

Seizures, fever, cardiotoxicity, rhabdomyolysis, acute kidney damage, coronary arterial thrombosis, and death.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Alcohol, Opioids, Benzodiazepines, and GHB/GBL

Synergistic coma, loss of airway protection during vomiting, and fatal respiratory/cardiac arrest.

Stimulants / Cathinones (e.g., N-Ethylhexedrone — forensic co-detection documented, Cocaine, alpha-PVP) and Lithium

ADB-FUBINACA carries documented coronary arterial thrombosis and cardiotoxic risk; co-ingesting stimulants triggers fatal myocardial ischemia, arrhythmias, and seizures.

Other Synthetic Cannabinoids (5F-MDMB-PINACA, AB-FUBINACA, ADB-PINACA, MDMB-4en-PINACA)

Frequently co-detected in severe poisonings; additive full CB1 overstimulation precipitates rapid coma, convulsions, and rhabdomyolysis.

Elevated Hazard — Avoid

Psychedelics, Dissociatives, and Tramadol

Triggers severe psychotic panic, delirium, and lowered seizure threshold.

Caution / Receptor Attenuation

Botanical Cannabis

Never apply to or mix with cannabis flower; creates lethal quantitative brackets hot-spots.

Structural Isomer & Sibling Comparison

ADB-FUBINACA (CB1 Ki = 0.36 nM, EC50 = 0.98–1.2 nM, 4-fluorobenzyl tail) sits just behind ADB-PINACA (EC50 0.52 nM) and 5F-MDMB-PINACA (EC50 0.59 nM) in potency—making it ~3.6–10x lower in EC50 than MDMB-4en-PINACA (4.3 nM) and ADB-BUTINACA (6.36–11.5 nM), and up to 140x stronger than botanical THC. Its smoked/inhaled duration is notably fast and compact (10–15 s onset, up to 60 min duration), which can tempt premature repeated exposure.

Physicochemical Stability & Storage

Physical Form: White neat crystalline solid or fine white powder (fusion/melting point 135–137 °C; NEVER supplied on sprayed herbs). · Soluble in DMSO and ethanol; practically insoluble in water.

High stability (remains stable for >315 days at 20 °C and >105 days at 4 °C / -20 °C); store dry, sealed, and protected from light.

Cross-Tolerance & Dependence Profile

Rapid CB1 downregulation and cross-tolerance with all cannabinoids; chronic exposure carries high dependence liability and preclinical evidence of neuronal mitochondrial dysfunction.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
CB₁ / CB₂ Cannabinoid receptors CB1 and CB2

CB1 and CB2 are the two cannabinoid receptors named on these cards. Papers usually discuss CB1 in the nervous system and CB2 more often in immune tissue. The number beside them is often a Ki in nanomoles.

EC₅₀ / IC₅₀ Halfway concentration

EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.

Kᵢ Binding tightness in nanomoles

Ki says how tightly a compound sits on a receptor in a binding test. It is written in nanomoles per litre. A Ki of 1 nM means very tight binding in that experiment.

ratio Selectivity ratio

A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.

CAS CAS registry number

A CAS number is a passport number for one chemical entry in the CAS registry. The free base and a salt of the same parent usually have different CAS numbers.

IUPAC IUPAC Name & Molecular Formula

The molecular formula counts how many atoms of each element sit in one molecule, while the IUPAC name is the systematic map showing exactly how those atoms are connected.

CID / InChIKey PubChem CID & Standard InChIKey

PubChem CID is the catalog number in the U.S. National Library of Medicine chemistry database, and InChIKey is a 27-character digital fingerprint of the molecule's exact 3D structure.

1 mg / µg Calibrated Physical Form (1 mg Tablets, µg Liquid, Crystal)

Milligram-scale benzodiazepines are supplied as 1 mg tablets (1 tablet = 1 mg), microgram lysergamides as dissolved liquid (µg), and standard compounds as pure crystal or powder.

Comprehensive Analytical & Toxicological Monograph

ADB-FUBINACA (ADMB-FUBINACA; N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-car boxamide; CAS 1445583-51-6 [patent CAS 1185282-00-1], PubChem CID 70969086) is a para-fluorobenzyl indazole-3-carboxamide originally patented by Pfizer in 2009 and supplied strictly as a pure analytical white crystalline solid or powder (`pure_powder_or_crystal`, C21H23FN4O2, 382.44 g/mol, mp 135–137 °C — never on sprayed herbs). Pharmacologically, ADB-FUBINACA acts as a sub-nanomolar full agonist at human CB1 (Ki = 0.36 nM; EC50 = 0.98–1.2 nM, up to 140-fold more potent than Delta9-THC with ~3x the maximal efficacy of JWH-018) and CB2 receptors (EC50 = 3.5 nM). Peer-reviewed reviews note that when inhaled, effects begin almost immediately (10–15 seconds) and last up to 60 minutes. Because unweighed pure powder cannot be safely measured on a milligram scale, strict volumetric dilution is mandatory: tentative microgram harm-reduction estimates place threshold effects at 25–50 ug, light relaxation at 50–125 ug, common heavy cannabimimetic sedation at 125–250 ug, strong confusion, chest pain, and paranoia at 250–500 ug, and life-threatening overdose at 500+ ug (0.50+ mg), where clinical and autopsy literature documents coma, seizures, rhabdomyolysis, kidney damage, and fatal coronary arterial thrombosis. Within our synthetic cannabinoid series, ADB-FUBINACA ranks just behind 5F-MDMB-PINACA and ADB-PINACA in receptor potency while exceeding MDMB-4en-PINACA and ADB-BUTINACA ~3.6–10-fold, with the fastest onset and most compact inhaled arc (~60 min) of the group. Never combine with alcohol, opioids, benzodiazepines, GHB/GBL, stimulants (such as Hexen or cocaine), other cannabinoids, or lithium.

Chemical Architecture & Structural Profile

ADB-FUBINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide) is a reference compound belonging to the Cannabinoids (Indazole carboxamides) class, characterized by the molecular formula C21H23FN4O2 and a molar mass of 382.4 g/mol. The parent molecule is indexed under CAS registry number 1185282-00-1 and in the NCBI PubChem database as CID 58124399 (Standard InChIKey: ZSSGCSINPVBLQD-GOSISDBHSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), ADB-FUBINACA is indexed within the Cannabinoids (Indazole carboxamides) structural group. Synthetic indazole carboxamide exhibiting high receptor affinity in in-vitro assays; requires calibrated micro-analytical balances and full dermal and respiratory protection. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations